{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33309815",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "12",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.addr.2020.12.004",
      "S0169-409X(20)30275-1"
    ],
    "Journal": {
      "ISSN": "1872-8294",
      "JournalIssue": {
        "Volume": "169",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "Advanced drug delivery reviews",
      "ISOAbbreviation": "Adv Drug Deliv Rev"
    },
    "ArticleTitle": "Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.",
    "Pagination": {
      "StartPage": "100",
      "EndPage": "117",
      "MedlinePgn": "100-117"
    },
    "Abstract": {
      "AbstractText": [
        "To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with categorical failures in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in development, and present the evidence supporting inhaled delivery of antiviral mAb as an early intervention against COVID-19 that could prevent important pulmonary morbidities associated with the infection."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA."
          }
        ],
        "LastName": "Cruz-Teran",
        "ForeName": "Carlos",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA."
          }
        ],
        "LastName": "Tiruthani",
        "ForeName": "Karthik",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Inhalon Biopharma, Durham, NC 27709, USA."
          }
        ],
        "LastName": "McSweeney",
        "ForeName": "Morgan",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA."
          }
        ],
        "LastName": "Ma",
        "ForeName": "Alice",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA."
          }
        ],
        "LastName": "Pickles",
        "ForeName": "Raymond",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Inhalon Biopharma, Durham, NC 27709, USA; UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: lai@unc.edu."
          }
        ],
        "LastName": "Lai",
        "ForeName": "Samuel K",
        "Initials": "SK"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R43 AI138728",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R43 AI149894",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R44 AI141054",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "UL1 TR002489",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R43 AI155185",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R44 AI138728",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, Non-P.H.S.",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Adv Drug Deliv Rev",
    "NlmUniqueID": "8710523",
    "ISSNLinking": "0169-409X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunologic Factors"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "metabolism"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "chemistry",
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Monoclonal"
    },
    {
      "QualifierName": [
        "chemistry",
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "metabolism",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunization, Passive"
    },
    {
      "QualifierName": [
        "chemistry",
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Immunologic Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Structure, Secondary"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Structure, Tertiary"
    },
    {
      "QualifierName": [
        "chemistry",
        "drug effects",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "Virus Shedding"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Serotherapy"
    }
  ]
}